Effects of Sunitinib in the Expression of VEGF and of Interleukin 8: Explanation of Anti-angiogenic Effects.

Trial Profile

Effects of Sunitinib in the Expression of VEGF and of Interleukin 8: Explanation of Anti-angiogenic Effects.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms SUVEGIL
  • Most Recent Events

    • 29 Aug 2017 Results (n=99) of SUVEGIL and TORAVA trials ,published in the British Journal of Cancer.
    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top